Stuart Naylor, serving as the Chief Scientific Officer for Ophthalmology at MeiraGTx Holdings plc (NASDAQ: MGTX), sold ordinary shares with a total value of $409,470 on July 7, 2026. These transactions were executed at prices ranging from $13.86 to $14.9 per share. The sales were facilitated through a Rule 10b5-1 trading plan, which Naylor adopted on December 9, 2025. The timing of this divestment occurs as MGTX stock has surged 101% over the past six months, with shares currently trading at $14.64, a level near the 52-week high of $15.35. According to InvestingPro analysis, the stock appears overvalued at current levels.
The transactions included the sale of 2,547 ordinary shares at a weighted average price of $13.86 per share, and an additional 25,112 ordinary shares at a weighted average price of $14.90 per share. Following these transactions, Naylor directly holds 640,846 ordinary shares of MeiraGTx Holdings plc. The reporting person has committed to provide full information regarding the number of shares sold at each separate price upon request.
In other recent news, MeiraGTx Holdings plc has secured up to $400 million in funding from Oberland Capital Management LLC. This investment includes $375 million in non-dilutive capital through capped royalty payments on specific products and an additional $25 million in equity. Meanwhile, MeiraGTx and Hologen Limited have finalized strategic collaboration and licensing agreements, focusing on gene therapies for Parkinson’s disease and genetic obesity disorders. The collaboration also includes a proprietary device for delivering gene therapy to the central nervous system.
In corporate governance developments, MeiraGTx held its annual general meeting, where shareholders elected three Class II directors and approved the auditor. Piper Sandler has raised its price target for MeiraGTx to $30, maintaining an Overweight rating, citing durable three-year data for the company’s xerostomia treatment. H.C. Wainwright reiterated a Buy rating with a $20 price target, highlighting progress in gene therapy and confidence in the AQUAx2 program. These recent developments reflect ongoing strategic and financial activities at MeiraGTx.